Schrödinger Reports Second Quarter 2025 Financial Results
Second Quarter Total Revenue of
Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance
Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development
Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025
"In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven computational technologies to accelerate molecular discovery,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “In addition to progressing several collaborative programs in our pipeline, we achieved an important milestone with the presentation of encouraging initial data for our MALT1 inhibitor, SGR-1505, and we expect to report initial data from our other two clinical programs in the fourth quarter.”
Earlier this year, Schrödinger presented initial Phase 1 data for SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be well tolerated and clinically active with responses observed in multiple histologies, including in patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.
“We are very pleased with the initial Phase 1 SGR-1505 data we presented last month at EHA and ICML. We are exploring strategic opportunities for SGR-1505 with the goals of accelerating the clinical development of this potential best-in-class molecule and maximizing benefit to patients globally,” stated Karen Akinsanya, Ph.D., president, head of therapeutics R&D and chief strategy officer, partnerships. “In parallel, we plan to complete the Phase 1 package and meet with the FDA later this year to discuss the recommended Phase 2 dose.”
Second Quarter 2025 Financial Results
-
Total revenue for the second quarter increased
16% to$54.8 million $47.3 million -
Software revenue for the second quarter increased
15% to$40.5 million $35.4 million -
Drug discovery revenue was
$14.2 million $11.9 million -
Software gross margin was
68% for the second quarter, compared to80% in the second quarter of 2024, primarily reflecting the costs associated with the company’s predictive toxicology initiative. -
Operating expenses were
$79.1 million $84.1 million -
Other income was
$10.0 million $1.2 million -
Net loss for the second quarter was
$43.2 million $54.0 million
|
Three Months Ended |
|||||||||
June 30, |
||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
% Change |
|
|
(in millions) |
|
|
|||||||
Total revenue |
$ |
54.8 |
|
|
$ |
47.3 |
|
|
16 |
% |
Software revenue |
|
40.5 |
|
|
|
35.4 |
|
|
15 |
% |
Drug discovery revenue |
|
14.2 |
|
|
|
11.9 |
|
|
19 |
% |
Software gross margin |
|
68 |
% |
|
|
80 |
% |
|
|
|
Operating expenses |
$ |
79.1 |
|
|
$ |
84.1 |
|
|
(6.0 |
)% |
Other income (expense) |
$ |
10.0 |
|
|
$ |
(1.2 |
) |
|
— |
|
Net loss |
$ |
(43.2 |
) |
|
$ |
(54.0 |
) |
|
— |
|
For the three and six months ended June 30, 2025, Schrödinger reported a non-GAAP net loss of
2025 Financial Outlook
As of August 6, 2025, Schrödinger updated its expectation for operating expenses and reaffirmed the other aspects of its previously issued financial guidance for the fiscal year ending December 31, 2025:
-
Software revenue growth is expected to range from
10% to15% . -
Drug discovery revenue is expected to range from
$45 million $50 million -
Software gross margin is expected to range from
74% to75% . - Operating expenses in 2025 are now expected to be lower than 2024.
- Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.
For the third quarter of 2025, software revenue is expected to range from
Key Highlights
Proprietary and Collaborative Pipeline
- In June, Schrödinger presented encouraging initial Phase 1 clinical data for SGR-1505, the company’s MALT1 inhibitor in patients with relapsed/refractory B-cell malignancies. These data were presented at the European Hematology Association Annual Congress and International Conference on Malignant Lymphoma. Also in June, SGR-1505 received Fast Track Designation from the FDA for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Schrödinger is completing the Phase 1 package and expects to meet with the FDA later this year to discuss the recommended Phase 2 dose. The company is also exploring strategic opportunities to advance the development of SGR-1505.
- Schrödinger is continuing to progress the Phase 1 clinical study of SGR-2921, the company’s CDC7 inhibitor, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Initial clinical data from this study are expected in the fourth quarter of 2025.
- Schrödinger is continuing to progress the Phase 1 clinical study of SGR-3515, the company’s Wee1/Myt1 co-inhibitor, in patients with advanced solid tumors. Initial clinical data from this study are expected in the fourth quarter of 2025.
- In July, Schrödinger announced an expanded research collaboration with Ajax Therapeutics, a company co-founded by Schrödinger. The expansion adds a new Janus kinase (JAK) target to the collaboration. Under the terms of the amended collaboration agreement, Schrödinger is eligible to receive discovery and development milestones for the new target similar to the terms of the original collaboration agreement. Schrödinger is also eligible to receive sales milestones and single-digit royalties on net sales of any products emerging from the additional target.
Platform
- Scientists at Schrödinger, Sanofi, Galapagos and UCB published an industry perspective on computational hit-finding in the Journal of Medicinal Chemistry. The paper highlights how recent breakthroughs in computational power, AI, and expansive chemical libraries are reshaping virtual screening and hit identification, and emphasizes the importance of accurate physics-based methods, including Schrödinger’s FEP+.
Corporate
-
In May, the company completed a review of the organization and implemented several changes to improve its operating expense profile and reduce cash burn, including a reduction in force of approximately
7% of full-time employees, which is expected to reduce operating expenses by approximately$30 million
Webcast and Conference Call Information
Schrödinger will host a conference call to discuss its second quarter 2025 financial results on Wednesday, August 6, 2025, at 4:30 p.m. ET. The live webcast can be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.
Non-GAAP Information
Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in
Other companies in Schrödinger’s industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2025 and third quarter ending September 30, 2025, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, including its ability to improve drug discovery, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its MALT1, CDC7, Wee1/Myt1, and SOS1 inhibitors, including SGR-1505, SGR-2921, SGR-3515, and SGR-4174, the clinical potential and favorable properties of its collaborators’ product candidates, the potential for SGR-1505 to be used for the treatment of relapsed/refractory B-cell malignancies, including Waldenström macroglobulinemia and chronic lymphocytic leukemia, the potential benefits of Fast Track designation, including frequency of interactions with the FDA during clinical development and potentially accelerated approval and/or priority review, its plans to explore strategic opportunities for the continued clinical development of SGR-1505, and Schrödinger’s plans to engage with regulators, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the
Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share amounts) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Revenues: |
|
|
|
|
|
|
|
||||||||
Software products and services |
$ |
40,544 |
|
|
$ |
35,404 |
|
|
$ |
89,360 |
|
|
$ |
68,819 |
|
Drug discovery |
|
14,215 |
|
|
|
11,930 |
|
|
|
24,950 |
|
|
|
15,113 |
|
Total revenues |
|
54,759 |
|
|
|
47,334 |
|
|
|
114,310 |
|
|
|
83,932 |
|
Cost of revenues: |
|
|
|
|
|
|
|
||||||||
Software products and services |
|
13,029 |
|
|
|
7,167 |
|
|
|
26,551 |
|
|
|
15,143 |
|
Drug discovery |
|
15,572 |
|
|
|
8,832 |
|
|
|
30,477 |
|
|
|
18,564 |
|
Total cost of revenues |
|
28,601 |
|
|
|
15,999 |
|
|
|
57,028 |
|
|
|
33,707 |
|
Gross profit |
|
26,158 |
|
|
|
31,335 |
|
|
|
57,282 |
|
|
|
50,225 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
43,138 |
|
|
|
50,835 |
|
|
|
88,982 |
|
|
|
101,446 |
|
Sales and marketing |
|
10,734 |
|
|
|
9,693 |
|
|
|
21,101 |
|
|
|
19,864 |
|
General and administrative |
|
25,189 |
|
|
|
23,536 |
|
|
|
50,991 |
|
|
|
49,077 |
|
Total operating expenses |
|
79,061 |
|
|
|
84,064 |
|
|
|
161,074 |
|
|
|
170,387 |
|
Loss from operations |
|
(52,903 |
) |
|
|
(52,729 |
) |
|
|
(103,792 |
) |
|
|
(120,162 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Gain on equity investments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Change in fair value of equity investments |
|
4,579 |
|
|
|
(5,833 |
) |
|
|
(8,516 |
) |
|
|
2,304 |
|
Other income |
|
5,438 |
|
|
|
4,598 |
|
|
|
9,642 |
|
|
|
9,626 |
|
Total other income (expense) |
|
10,017 |
|
|
|
(1,235 |
) |
|
|
1,126 |
|
|
|
11,930 |
|
Loss before income taxes |
|
(42,886 |
) |
|
|
(53,964 |
) |
|
|
(102,666 |
) |
|
|
(108,232 |
) |
Income tax expense |
|
287 |
|
|
|
83 |
|
|
|
315 |
|
|
|
539 |
|
Net loss |
$ |
(43,173 |
) |
|
$ |
(54,047 |
) |
|
$ |
(102,981 |
) |
|
$ |
(108,771 |
) |
Net loss per share of common and limited common stockholders, basic and diluted: |
$ |
(0.59 |
) |
|
$ |
(0.74 |
) |
|
$ |
(1.41 |
) |
|
$ |
(1.50 |
) |
Weighted average shares used to compute net loss per share of common and limited common stockholders, basic and diluted: |
|
73,427,635 |
|
|
|
72,711,685 |
|
|
|
73,243,797 |
|
|
|
72,501,409 |
|
Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except for share and per share amounts) |
|||||||
Assets |
June 30, 2025 |
|
December 31, 2024 |
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
219,901 |
|
|
$ |
147,326 |
|
Restricted cash |
|
12,079 |
|
|
|
15,331 |
|
Marketable securities |
|
230,284 |
|
|
|
204,798 |
|
Accounts receivable, net of allowance for doubtful accounts of |
|
10,073 |
|
|
|
235,692 |
|
Unbilled and other receivables, net of allowance for unbilled receivables of |
|
26,711 |
|
|
|
19,641 |
|
Prepaid expenses |
|
14,947 |
|
|
|
12,205 |
|
Total current assets |
|
513,995 |
|
|
|
634,993 |
|
Property and equipment, net |
|
21,709 |
|
|
|
24,196 |
|
Equity investments |
|
34,691 |
|
|
|
43,208 |
|
Goodwill |
|
4,791 |
|
|
|
4,791 |
|
Right of use assets - operating leases |
|
107,346 |
|
|
|
111,883 |
|
Other assets |
|
5,712 |
|
|
|
4,155 |
|
Total assets |
$ |
688,244 |
|
|
$ |
823,226 |
|
Liabilities and Stockholders' Equity: |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
|
8,800 |
|
|
$ |
10,666 |
|
Accrued payroll, taxes, and benefits |
|
25,322 |
|
|
|
42,110 |
|
Deferred revenue |
|
94,543 |
|
|
|
111,944 |
|
Lease liabilities - operating leases |
|
16,841 |
|
|
|
16,755 |
|
Other accrued liabilities |
|
10,263 |
|
|
|
10,272 |
|
Total current liabilities |
|
155,769 |
|
|
|
191,747 |
|
Deferred revenue, long-term |
|
91,995 |
|
|
|
108,814 |
|
Lease liabilities - operating leases, long-term |
|
97,472 |
|
|
|
101,074 |
|
Other liabilities, long-term |
|
136 |
|
|
|
146 |
|
Total liabilities |
|
345,372 |
|
|
|
401,781 |
|
Stockholders' equity: |
|
|
|
||||
Preferred stock, |
|
— |
|
|
|
— |
|
Common stock, |
|
644 |
|
|
|
637 |
|
Limited common stock, |
|
92 |
|
|
|
92 |
|
Additional paid-in capital |
|
970,687 |
|
|
|
946,037 |
|
Accumulated deficit |
|
(628,522 |
) |
|
|
(525,541 |
) |
Accumulated other comprehensive (loss) income |
|
(29 |
) |
|
|
220 |
|
Total stockholders' equity |
|
342,872 |
|
|
|
421,445 |
|
Total liabilities and stockholders' equity |
$ |
688,244 |
|
|
$ |
823,226 |
|
Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) |
|||||||
|
Six Months Ended June 30, |
||||||
|
|
2025 |
|
|
|
2024 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(102,981 |
) |
|
$ |
(108,771 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Gain on equity investments |
|
— |
|
|
|
— |
|
Fair value adjustments of equity investments |
|
8,516 |
|
|
|
(2,304 |
) |
Depreciation and amortization |
|
3,120 |
|
|
|
2,837 |
|
Stock-based compensation |
|
22,201 |
|
|
|
25,026 |
|
Noncash investment accretion |
|
(1,676 |
) |
|
|
(4,706 |
) |
Loss on disposal of property and equipment |
|
20 |
|
|
|
7 |
|
Decrease (increase) in assets: |
|
|
|
||||
Accounts receivable, net |
|
225,619 |
|
|
|
54,143 |
|
Unbilled and other receivables |
|
(7,070 |
) |
|
|
(17,197 |
) |
Reduction in the carrying amount of right of use assets - operating leases |
|
4,537 |
|
|
|
4,205 |
|
Prepaid expenses and other assets |
|
(4,299 |
) |
|
|
(6,118 |
) |
(Decrease) increase in liabilities: |
|
|
|
||||
Accounts payable |
|
(1,737 |
) |
|
|
(8,941 |
) |
Accrued payroll, taxes, and benefits |
|
(16,788 |
) |
|
|
(7,443 |
) |
Deferred revenue |
|
(34,220 |
) |
|
|
(17,395 |
) |
Lease liabilities - operating leases |
|
(3,516 |
) |
|
|
(3,953 |
) |
Other accrued liabilities |
|
139 |
|
|
|
(2,389 |
) |
Net cash provided by (used in) operating activities |
|
91,865 |
|
|
|
(92,999 |
) |
Cash flows from investing activities: |
|
|
|
||||
Purchases of property and equipment |
|
(910 |
) |
|
|
(5,096 |
) |
Purchases of equity investments |
|
— |
|
|
|
(3,000 |
) |
Purchases of marketable securities |
|
(166,062 |
) |
|
|
(153,513 |
) |
Proceeds from maturity of marketable securities |
|
142,003 |
|
|
|
196,266 |
|
Net cash (used in) provided by investing activities |
|
(24,969 |
) |
|
|
34,657 |
|
Cash flows from financing activities: |
|
|
|
||||
Proceeds from issuances of common stock upon stock option exercises |
|
2,456 |
|
|
|
950 |
|
Principal payments on finance leases |
|
(29 |
) |
|
|
(29 |
) |
Payment of offering costs |
|
— |
|
|
|
— |
|
Proceeds from issuance of common stock in ATM offering |
|
— |
|
|
|
8,691 |
|
Net cash provided by financing activities |
|
2,427 |
|
|
|
9,612 |
|
Net increase (decrease) in cash and cash equivalents and restricted cash |
|
69,323 |
|
|
|
(48,730 |
) |
Cash and cash equivalents and restricted cash, beginning of period |
|
162,657 |
|
|
|
161,066 |
|
Cash and cash equivalents and restricted cash, end of period |
$ |
231,980 |
|
|
$ |
112,336 |
|
|
|
|
|
||||
Supplemental disclosure of cash flow and noncash information |
|
|
|
||||
Cash paid for income taxes |
$ |
365 |
|
|
$ |
439 |
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
||||
Purchases of property and equipment in accounts payable |
|
34 |
|
|
|
435 |
|
Purchases of property and equipment in accrued liabilities |
|
— |
|
|
|
331 |
|
Acquisition of right of use assets - operating leases, contingency resolution |
|
— |
|
|
|
2,848 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) |
|||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
June 30, |
|
June 30, |
|||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
(in thousands, except per share data) |
||||||||||||||
Net loss (GAAP) |
$ |
(43,173 |
) |
|
$ |
(54,047 |
) |
|
$ |
(102,981 |
) |
|
$ |
(108,771 |
) |
Income tax expense |
|
287 |
|
|
|
83 |
|
|
|
315 |
|
|
|
539 |
|
Gain on equity investment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Change in fair value |
|
(4,579 |
) |
|
|
5,833 |
|
|
|
8,516 |
|
|
|
(2,304 |
) |
Non-GAAP net loss |
$ |
(47,465 |
) |
|
$ |
(48,131 |
) |
|
$ |
(94,150 |
) |
|
$ |
(110,536 |
) |
Non-GAAP net loss per share of common and limited common stockholders, basic and diluted: |
$ |
(0.65 |
) |
|
$ |
(0.66 |
) |
|
$ |
(1.29 |
) |
|
$ |
(1.52 |
) |
Weighted average shares used to compute non-GAAP net loss per share of common and limited common stockholders, basic and diluted: |
|
73,427,635 |
|
|
|
72,711,685 |
|
|
|
73,243,797 |
|
|
|
72,501,409 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806269302/en/
Matthew Luchini (Investors)
Schrödinger, Inc.
matthew.luchini@schrodinger.com
917-719-0636
Allie Nicodemo (Media)
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325
Source: Schrödinger
